Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Christian Ruff
Mr Manesh Patel
By Christian Ruff, (Boston, United States of America)View Discussant report
Open the PresentationWatch the Webcast
List of AuthorsChristian T. Ruff, MD, MPH, Robert P. Giugliano, MD, SM, Eugene Braunwald, MD, David A. Morrow, MD, MPH, Sabina A. Murphy, MPH, Julia F. Kuder, MPH, Naveen Deenadayalu, MPH, Petr Jarolim, MD, PhD, Joshua Betcher, PhD, Minggao Shi, PhD, Karen Brown, PhD, Indu Patel, MD, Michele Mercuri, MD, PhD, Elliott M. Antman, MD
BackgroundThe ENGAGE AF-TIMI 48 trial in 21,105 patients with AF showed that both the high (HD) and low dose (LD) regimens of the factor Xa (FXa) inhibitor edoxaban were as effective as warfarin in preventing stroke or systemic embolism (SEE), while reducing major bleeding and cardiovascular death (CVD). The relationships between edoxaban dose, pharmacokinetics, pharmacodynamics, and clinical outcomes have not been previously reported.MethodsWe correlated edoxaban dose, concentration, and anti-FXa activity and compared efficacy and safety outcomes with warfarin stratified by dose reduction status.ResultsPatients who met clinical criteria for dose reduction had higher stroke, bleeding, and CVD rates. The dose of edoxaban ranged from 15 - 60 mg, resulting in a 2 to 3-fold gradient of mean drug exposure (16.0 - 48.5 ng/mL) and mean anti-FXa activity (0.35 - 0.85 IU/mL). Dose reduction decreased mean exposure by 29% and 35% and mean anti-FXa activity by 25% and 20% in the HD and LD regimens, respectively. Despite the decrease in anti-FXa activity, dose reduction preserved the relative efficacy of edoxaban compared with warfarin (stroke or SEE: HD p-interaction=0.85, LD p-interaction=0.99) and provided even greater safety (major bleeding: HD p-interaction 0.02, LD p-interaction=0.002). ConclusionThis first analysis of an oral anticoagulant that combines pharmacokinetic, pharmacodynamics, and clinical outcomes demonstrates that dose reduction lowered HD and LD edoxaban concentrations and anti-FXa levels, yet preserved efficacy with even greater relative reductions in bleeding compared with warfarin. The therapeutic window appears narrower for bleeding than thromboembolism.
By Manesh Patel, (Durham, United States of America)See Presenter abstract
Open the presentationWatch the Webcast
Clinical Trial Update Hot Line: Stable CAD and atrial fibrillation